PharmacoScan™ Solution consists of array plates, reagents, instrument consumables, and analysis software. It provides a cost-effective, reproducible, and scalable solution for translational researchers in health care organizations, pharmaceutical companies, and research institutes to study how genetic variations affect prescription drug absorption, distribution, metabolism, and excretion (ADME). By pre-emptively screening samples, the solution provides researchers with insight into pharmacogenomic risk factors in phase I and phase II enzymes, regulatory and/or modifier genes, drug target genes, and phase III/transporter genes.

To learn more, visit the PharmacoScan Solution product web page
 

  1. Obtain biologically relevant data from greater than 99% of markers in the CPIC, PharmGBK and PharmADME working groups recommended list.

  2. Assesses 4,627 ADME markers within 1,191 genes known to play roles in drug processing.

  3. Includes highly predictive markers in critical genes like CYP2D6, CYP2C9, and CYP4F2 as well as copy number variation calling.

  4. Based on the proven Axiom™ technology, which provides precision, reproducibility, and scalability.

Thermo Fisher offers a range of solutions to meet the needs of researcher’s developing psychotropic, cancer, pain, and cardiovascular medications. Learn more about these solutions. For those translational researchers seeking insight into 4,627 ADME genetic markers within 1,191 genes and select ADME gene copy number variants using one assay, the PharmacoScan Solution for microarray genotyping is a robust and cost-effective approach that is scalable to high-throughput sample processing.

To download the PGRN Symposium and ASHG scientific posters, please complete the following:

*
*
*
*
*